IDO1 and melanoma: In a phase-I/II trial, a more potent IDO1 inhibitor, BMS-986205, was added to nivolumab or nivolumab plus ipilimumab treating 627 patients with advanced cancers including melanoma, and results are awaited (NCT02658890).